Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.

P James B DyckTeresa CoelhoMarcia Waddington CruzThomas H BrannaganSami KhellaChafic KaramJohn L BerkMichael J PolydefkisJohn C KincaidJanice F WiesmanWilliam J LitchyMichelle L MauermannElizabeth J AckermannBrenda F BakerShiangtung W JungSpencer GuthrieMichael PollockPeter J Dyck

Published in: Muscle & nerve (2020)

Inotersen treatment stabilized neuropathy symptoms, including autonomic symptoms, in patients with hATTR according to NSC score. Thus, the NSC may be an effective measure to assess neuropathy progression and patients' neuropathy experience in clinical practice.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
heart rate variability
peritoneal dialysis
sleep quality
blood pressure
physical activity
combination therapy
patient reported outcomes